Foghorn Therapeutics Provides Corporate Update

Foghorn Therapeutics Provides Corporate Update

News Highlights

– Received IND clearance for FHD-609, a targeted protein degrader, which is being developed for the treatment of synovial sarcoma

– Continued to advance broad therapeutic pipeline targeting the chromatin regulatory system

CAMBRIDGE, Mass., May 11, 2021 (News) — Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today provided a corporate update in conjunction with its 10-Q filing for the quarter ended March 31, 2021.

“2021 has already been a year of significant progress for our clinical programs, with FHD-609 recently becoming our second drug candidate to enter the clinic,” said Adrian Gottschalk, Chief Executive Officer of Foghorn Therapeutics. “FHD-609, a protein degrader targeting BRD9, is initially being evaluated as a treatment for synovial sarcoma. FHD-609 demonstrates Foghorn’s capabilities to develop protein degraders.”

Continued Mr. Gottschalk: “Our first program, FHD-286, is being evaluated in two separate phase I studies, one in relapsed and/or refractory AML and MDS, and a second in metastatic uveal melanoma. We look forward to generating clinical data over the next year with the first drugs to enter the clinic from our proprietary Gene Traffic Control® platform.”

“Beyond these first two programs, we continue to advance multiple drug candidates targeting the chromatin regulatory system including protein degraders, enzymatic inhibitors and transcription factor disruptors.”

Recent Corporate Highlights:

  • Received IND clearance for FHD-609. Foghorn received FDA clearance of its IND application for FHD-609. FHD-609 is a highly potent, selective, intravenous, small molecule protein degrader of BRD9, initially being developed for the treatment of synovial sarcoma with the intention to expand into additional indications, including SMARCB1 deleted tumors.
  • Received IND clearance for FHD-286. Foghorn received FDA clearance of its IND application for FHD-286 for (i) relapsed and/or refractory AML and MDS and (ii) metastatic uveal melanoma. FHD-286, is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM.
  • Appointed Ian Smith to Board of Directors. On April 27th, 2021 Foghorn appointed Ian Smith to its Board of Directors, adding a diverse skill set spanning decades as a proven biotechnology leader.

Key Upcoming Milestones

  • FHD-286 data. Foghorn expects to have initial data from its phase 1 studies of FHD-286 in metastatic uveal melanoma and relapsed/refractory AML as early as year-end 2021.
  • FHD-609 data. Foghorn expects to have initial data from its phase 1 study in synovial sarcoma as early as the first half of 2022.

Upcoming Events

  • June 15th Investor Event. Foghorn will host its inaugural Chromatin Regulatory System Investor Event virtually on June 15th, 2021. Investors can register for the event HERE.
  • Jefferies Virtual Healthcare Conference. Company presentation, June 1, 2021 at 10:00am ET.
  • Goldman Sachs 42nd Annual Healthcare Conference (Virtual), June 8-10, 2021.

Financial Condition

Foghorn reported cash, cash equivalents and marketable securities of $ 160.9 million as of March 31, 2021, as compared to $185.8 million as of December 31, 2020.

About Foghorn Therapeutics

Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

Forward-Looking Statements

This press release contains “forward-looking statements” regarding the Company’s approach to treating disease. Forward-Forward-looking statements include statements regarding the Company’s clinical trial, product candidates and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risk regarding the timing of filing an IND for our product candidates and other factors set forth under the heading “Risk Factors” in the Company’s Form 10-K. Any forward-looking statement made in this press release speaks only as of the date on which it is made.

Media Contact:

Fanny Cavalié, Foghorn Therapeuticsfcavalie@foghorntx.com

Gregory Kelley, Ogilvygregory.kelley@ogilvy.com

Investor Relations Contact:

Allan Reine, Foghorn Therapeuticsareine@foghorntx.com

Hans Vitzthum, LifeSci Advisors617-430-7578hans@lifesciadvisors.com

  • Check the latest Health news updates and information.
  • Please share this news Foghorn Therapeutics Provides Corporate Update with your friends and family to support us your one share helps us a lot.
Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
ABOUT MONEY: Non-cash contributions to charities |  Features

ABOUT MONEY: Non-cash contributions to charities | Features

A qualified appraiser must regularly prepare appraisals for which he or she is paid, and the individual must demonstrate verifiable education and experience in ...
E3 2021: Microsoft displays Halo Infinite, Starfield and Forza Horizon 5

E3 2021: Microsoft displays Halo Infinite, Starfield and Forza Horizon 5

A new Forza racing game and the Xbox release of Flight Simulator were also among the 30 titles revealed. It was the first E3 since Microsoft acquired ...
Finance or pay a car in cash when I have bad credit?

Finance or pay a car in cash when I have bad credit?

If you think your credit score is too low to get an auto loan, you could be right, after all, you know your credit situation better than anyone (right?)! ...
Snowbirds Pinch Riders, 3-2 |  News, Sports, Jobs

Snowbirds Pinch Riders, 3-2 | News, Sports, Jobs

“This was an excellent high school baseball game, which should be expected in a regional final,” Adams said. “We are extremely proud of the effort our kids put ...
Kaboxer, a tool for managing programmes in containers, is released by the Kali Linux team

With Linux 5.14, XFS will see a significant increase in scalability

The message on the merge further explains the code that’s been reworked in the XFS driver for better scalability around the CIl and log: The log write ...
Unsurprisingly Google  looking to Samsung for its foldable phone display

The launch dates for the Samsung Galaxy Z Fold3, Flip3, and Watch 4 have been suggested

Word comes from tipster Jon Prosser, who also claimed that Samsung will launch the Galaxy Watch4 and Watch Active4 before the two smartphones – on August 11. ...
Dutch Official Predicts Market Encryption Break, Says 'The Netherlands Should Ban Bitcoin Now' - Bitcoin Regulation News

Dutch Official Predicts Market Encryption Break, Says ‘The Netherlands Should Ban Bitcoin Now’ – Bitcoin Regulation News

The director continued: “Cryptocurrencies are essentially neither money nor a financial product, but an example of what Nobel laureate Robert Shiller calls a ...
Essential Inclusion to Achieve True Diversity in the Money Management Industry

Essential Inclusion to Achieve True Diversity in the Money Management Industry

CFA data show that about 75% of women’s decision-making on careers happens between the ages of 18 and 25, “which means we have to start presenting our industry ...
State Vet Recommends Mandatory Health Passports for Rodeo Horses – Dakota Free Press

State Vet Recommends Mandatory Health Passports for Rodeo Horses – Dakota Free Press

Source Horses must have a Certificate of Veterinary Inspection or EECVI and a negative Coggins test or ELISA Equine Infectious Anemia test to enter South ...
Wells Fargo, Bank of America Finance Predatory Lenders and Your Outrageous Interest Rates

Wells Fargo, Bank of America Finance Predatory Lenders and Your Outrageous Interest Rates

World Finance, another high-cost lender that offers installment loans, where a person borrows a set amount of money all at one time. The borrower then can ...
Show next
Compsmag - Latest News from tech, business and health
Logo